In a recent review of mineral and electrolyte disorders with SGLT2 inhibitor therapy, there were the postulated effects of SGLT2 inhibitors on serum electrolytes (sodium, potassium, and magnesium) that inhibition of SGLT2 receptors promotes glycosuria, natriuresis, and osmotic diuresis, which in turn causes an elevation of aldosterone activity with increased kaliuresis and magnesuria (20). The gene discussed is SLC5A2; the disease is Abnormal blood ion concentration.